Phaseline

Targets › KLRC1

KLRC1 (NKG2-A/NKG2-B type II integral membrane protein): drug programs, companies and trials

3 programs from 2 companies in 9 trials: 5 Phase 2, 2 Phase 1, 2 Phase 3; Oncology; next expected readout Jan 2027.

Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. (UniProt, P26715)

Open in Phaseline: the race on KLRC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaMonalizumab
NKG2-A/NKG2-B type II integral membrane protein inhibitor
KLRC1Phase 3Squamous Cell Carcinoma of the Head and Neck; Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Acute Myeloid Leukaemia …Jan 2027
AstraZenecaMonalizumab (IPH2201)
NKG2-A/NKG2-B type II integral membrane protein inhibitor
KLRC1Phase 1Advanced Solid TumorsJul 2027
Eastern Hepatobiliary Surgery HospitalSuper Hi-TCR-T cells
Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP
PVRL4, KLRC1, TROP2, B7H3, GPC3Phase 1Advanced Hepatocellular Carcinoma (HCC)Jan 2028

Conditions

Advanced Solid Tumors (1) Squamous Cell Carcinoma of the Head and Neck (1) Non-Small Cell Lung Cancer (1) Non-small Cell Lung Cancer (1) Acute Myeloid Leukaemia (1) Non-muscle Invasive Bladder Cancer (1) Extensive Stage Lung Small Cell Carcinoma (1) Small Cell Lung Cancer (1) Advanced Hepatocellular Carcinoma (HCC) (1)

Modalities

mixed (2), other (1)

Companies

AstraZeneca (2) Eastern Hepatobiliary Surgery Hospital (1)

Related targets

PVRL4 (1) TROP2 (1) B7H3 (1) GPC3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.